Investor Presentation H1 2023

14 Investor presentation First six months of 2023 Novo NordiskⓇ OASIS 1 trial with oral semaglutide 50 mg demonstrated superior weight loss in people with overweight or obesity vs placebo. OASIS 1 enrolled 667 patients with overweight or obesity OASIS 1 showed statistically significant weight loss vs placebo Mean baseline body weight: 105.4kg Oral Semaglutide 50 mg* R 1:1 Placebo* 68 Weeks 7 weeks follow-up Lifestyle intervention • Objective To compare the safety and efficacy of 50 mg oral semaglutide with placebo in people with overweight or obesity without T2D Co-primary endpoints Change in body weight (%) 0 3 6 -9 -12 -15 -18 048 12 16 20 28 36 44 52 -1.8 -17.4 60 60 68 68* • Percentage change in body weight from baseline to week 68 Achievement of ≥5% weight loss from baseline at week 68 Time since randomisation (weeks) Oral sema 50 mg Placebo *As an adjunct to a reduced calorie diet and increased physical activity in adults with obesity or with overweight and weight related comorbidities (Weight related comorbidities are hypertension, dyslipidaemia, obstructive sleep apnoea and CVD) Note: Observed data are on-treatment. Week 68* is the body weight change using the trial product estimand Sema: Semaglutide; T2D: Type 2 diabetes

View entire presentation